Shares (NASDAQ:AVIR) of Aviragen Therapeutics Inc. took a drubbing after the company reported following Wednesday's market close that its double-blind, placebo-controlled phase IIa study of BTA585 in adults challenged intranasally with respiratory syncytial virus (RSV) missed the primary endpoint of reducing viral load.